FirstIgnite is supporting the commercialization of the University of California, Davis’s new photodynamic therapy photosensitizer technology. This technology involves a self-assembling, fibrous photosensitizer designed to target the mitochondria within tumor cells. By utilizing photodynamic therapy, this approach enhances both the localization and potency of the treatment.
This technology is applicable to photosensitizers in photodynamic therapy and drug administration targeted directly to mitochondria. The photodynamic therapy market size was worth $4.05 billion in 2021 and is expected to reach $7.2 Billion by 2030.
The University of California, Davis’s photodynamic therapy photosensitizer technology is ready for collaboration (licensing, partnerships, industry feedback, etc.). Is your company the right fit? If you’d be available for a conversation with the University of California, Davis team, you can schedule a time directly on their team’s calendar here.